History of Changes for Study: NCT02420821

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma

A study version is represented by a row in the table.
Select two study versions to compare. One each from columns A and B.
Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
Click "Compare" to do the comparison and show the differences.
Select a version's Submitted Date link to see a rendering of the study for that version.
The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
Hover over the "Recruitment Status" to see how the study's recruitment status changed.
Study edits or deletions are displayed in red.
Study additions are displayed in green.

Study Record Versions

Version	Submitted Date	Changes
1	April 15, 2015	None (earliest Version on record)
2	May 11, 2015	Recruitment Status, Contacts/Locations and Study Status
3	May 29, 2015	Contacts/Locations and Study Status
4	June 1, 2015	Study Status
5	September 14, 2015	Contacts/Locations, Arms and Interventions, Study Status, Eligibility, Outcome Measures, Study Description and Study Identification
6	September 17, 2015	Contacts/Locations, Study Status and Study Identification
7	October 1, 2015	Contacts/Locations and Study Status
8	November 2, 2015	Contacts/Locations and Study Status
9	December 1, 2015	Contacts/Locations and Study Status
10	December 31, 2015	Contacts/Locations, Study Design and Study Status
11	February 11, 2016	Outcome Measures, Contacts/Locations, Arms and Interventions, Study Status, Study Identification, Eligibility and Study Description
12	March 1, 2016	Contacts/Locations and Study Status
13	April 2, 2016	Contacts/Locations and Study Status
14	May 4, 2016	Contacts/Locations and Study Status
15	June 1, 2016	Contacts/Locations and Study Status
16	July 1, 2016	Study Status, Contacts/Locations and Study Design
17	August 1, 2016	Contacts/Locations and Study Status
18	August 15, 2016	Contacts/Locations, Arms and Interventions and Study Status
19	September 1, 2016	Contacts/Locations and Study Status
20	October 3, 2016	Contacts/Locations and Study Status
21	November 1, 2016	Contacts/Locations and Study Status
22	February 28, 2017	Recruitment Status, Contacts/Locations, Arms and Interventions, Outcome Measures, Study Status, Study Design, Study Identification, Eligibility and Study Description
23	April 5, 2017	Study Status and Contacts/Locations
24	May 5, 2017	Contacts/Locations and Study Status
25	July 13, 2017	Contacts/Locations and Study Status
26	August 1, 2017	Study Status
27	January 8, 2018	Contacts/Locations and Study Status
28	January 12, 2018	Study Status
29	January 17, 2018	Study Status
30	February 28, 2018	Recruitment Status, Contacts/Locations, Study Status and Study Design
31	March 14, 2018	Recruitment Status, Study Status, Contacts/Locations and Study Design
32	April 2, 2018	Study Status and Contacts/Locations
33	April 23, 2018	Study Status
34	May 7, 2018	Study Status
35	June 4, 2018	Study Status
36	June 18, 2018	Study Status and Contacts/Locations
37	June 26, 2018	Study Status
38	July 30, 2018	Outcome Measures, Arms and Interventions, Study Status, Study Identification, Contacts/Locations, Eligibility and Study Description
	Results Submission Events
August 21, 2018 August 22, 2018		(Canceled on August 22, 2018) (Canceled on September 4, 2018)
39	September 4, 2018	Study Status, Outcome Measures, Contacts/Locations, Document Section and Results
40	November 26, 2018	Study Status
41	February 18, 2019	Study Status and Contacts/Locations
42	February 21, 2019	Study Status
43	May 13, 2019	Study Status and Contacts/Locations
44	August 5, 2019	Contacts/Locations and Study Status
45	September 9, 2019	Study Status and Contacts/Locations
46	September 16, 2019	Study Status
47	October 14, 2019	Study Status and Contacts/Locations
48	October 22, 2019	Contacts/Locations and Study Status
49	January 13, 2020	Study Status and Contacts/Locations
50	March 4, 2020	Study Status and Contacts/Locations
51	May 26, 2020	Contacts/Locations and Study Status
52	August 17, 2020	Contacts/Locations and Study Status
53	September 14, 2020	Study Status and Contacts/Locations
54	October 13, 2020	Study Status
55	January 20, 2021	Contacts/Locations and Study Status
56	March 18, 2021	Study Status and Contacts/Locations
57	May 6, 2021	Study Status
58	July 27, 2021	Study Status and Contacts/Locations
59	October 19, 2021	Contacts/Locations and Study Status
60	January 13, 2022	Recruitment Status, Study Status and Contacts/Locations
61	January 4, 2023	Adverse Events, Outcome Measures, Participant Flow, Study Status, Contacts/Locations and More Information

Comparison Format:

Merged
Side-by-Side

Study Identification


Unique Protocol ID:	WO29637
Brief Title:	A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma
Official Title:	A Phase III, Open-Label, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Secondary IDs:	2014-004684-20 [EudraCT Number]

Study Status


Record Verification:	September 2016
Overall Status:	Recruiting
Study Start:	May 2015
Primary Completion:	July 2020 [Anticipated]
Study Completion:	July 2020 [Anticipated]

First Submitted:	April 15, 2015
First Submitted that Met QC Criteria:	April 15, 2015
First Posted:	April 20, 2015 [Estimate]

Last Update Submitted that Met QC Criteria:	September 1, 2016
Last Update Posted:	September 2, 2016 [Estimate]

Sponsor/Collaborators


Sponsor:	Hoffmann-La Roche
Responsible Party:	Sponsor
Collaborators:

Oversight


U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring:

Study Description


Brief Summary:	This randomized, open-label study is designed to evaluate the efficacy and safety of atezolizumab (anti-programmed death ligand 1 [PD-L1] antibody) plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.
Detailed Description:

Conditions


Conditions:	Renal Cell Carcinoma
Keywords:

Study Design


Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 3
Interventional Study Model:	Parallel Assignment
Number of Arms:	2
Masking:	None (Open Label)
Allocation:	Randomized
Enrollment:	900 [Anticipated]

Arms and Interventions

Arms

Assigned Interventions

Experimental: Atezolizumab + Bevacizumab

Participants assigned to a dual regimen of atezolizumab plus bevacizumab will receive both agents for a maximum of approximately 5 years.

Drug: Atezolizumab [TECENTRIQ]

Atezolizumab will be given as a fixed dose of 1200 millgrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.

Other Names:

MPDL3280A

Drug: Bevacizumab

Bevacizumab will be given as 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.

Other Names:

Avastin

Experimental: Sunitinib

Participants assigned to receive sunitinib single-agent chemotherapy will receive treatment for a maximum of approximately 5 years.

Drug: Sunitinib

Sunitinib will be given as 50 mg orally (PO) once daily on Days 1 through 28 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.

Other Names:

Sutent

Outcome Measures


Primary Outcome Measures:
1.	Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in participants with detectable PD-L1 [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
2.	Overall survival (OS) in participants with detectable PD-L1 [ Time Frame: From randomization to death, loss to follow-up, or study end (up to 5 years) ]
Secondary Outcome Measures:
1.	PFS as determined by an independent review committee (IRC) using RECIST v1.1 [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
2.	Percentage of participants with objective response as determined by the investigator using RECIST v1.1 [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
3.	Duration of response (DOR) as determined by the investigator using RECIST v1.1 [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
4.	Percentage of participants with objective response as determined by an IRC using RECIST v1.1 [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
5.	DOR as determined by an IRC using RECIST v1.1 [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
6.	PFS as determined by the investigator using modified RECIST criteria [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
7.	Percentage of participants with objective response as determined by the investigator using modified RECIST criteria [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
8.	DOR as determined by the investigator using modified RECIST criteria [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
9.	PFS as determined by the investigator using RECIST v1.1 in all randomized participants and those with sarcomatoid histology [ Time Frame: Tumor assessments at Week 12, then every 6 weeks up to Week 78, then every 12 weeks until treatment discontinuation (up to 5 years) ]
10.	OS in participants with sarcomatoid histology [ Time Frame: Continously from randomization to treatment discontinuation (up to 5 years), then every 3 months until death, loss to follow-up, or study end (up to 5 years) ]
11.	Change from Baseline in symptom interference as measured by M.D. Anderson Symptom Inventory (MDASI) scores [ Time Frame: From Day 1 of Cycle 1 until 36 weeks after treatment discontinuation (up to 5 years) ]
12.	Change from Baseline in symptom severity as measured by MDASI scores [ Time Frame: From Day 1 of Cycle 1 until 36 weeks after treatment discontinuation (up to 5 years) ]
13.	Change from Baseline in symptom severity as measured by Brief Fatigue Inventory (BFI) scores [ Time Frame: From Day 1 of Cycle 1 until 36 weeks after treatment discontinuation (up to 5 years) ]
14.	Change from Baseline in treatment side effects as measured by Functional Assessment of Cancer Therapy Kidney Symptom Index (FSKI-19) subscale scores [ Time Frame: From Day 1 of Cycle 1 until 36 weeks after treatment discontinuation (up to 5 years) ]
15.	Change from Baseline in health-related quality of life as measured by European Quality of Life 5-Dimension (EQ-5D) scores [ Time Frame: From Day 1 of Cycle 1 until 36 weeks after treatment discontinuation (up to 5 years) ]
16.	Safety: Percentage of participants with adverse events [ Time Frame: Continously from randomization until 30 days after treatment discontinuation (up to 5 years) ]
17.	Safety: Percentage of participants with anti-therapeutic antibodies (ATAs) against atezolizumab [ Time Frame: Pre-dose (0 hours) on Day 1 of Cycles 1, 2, 4, and 8, and every eight cycles thereafter (cycle length of 42 days) until 120 days after treatment discontinuation (up to 5 years) ]
18.	Pharmacokinetics: Maximum serum concentration (Cmax) of atezolizumab [ Time Frame: 30 minutes post-dose on Day 1 of Cycle 1 ]
19.	Pharmacokinetics: Minimum serum concentration (Cmin) of atezolizumab [ Time Frame: Pre-dose (0 hours) on Days 1 and 22 of Cycles 1, 2, and 4; pre-dose (0 hours) on Day 1 of Cycle 8 and every eight cycles thereafter (cycle length of 42 days) until 120 days after treatment discontinuation (up to 5 years) ]
20.	Pharmacokinetics: Cmax of bevacizumab [ Time Frame: 30 minutes post-dose on Day 1 of Cycles 1 and 2 ]
21.	Pharmacokinetics: Cmin of bevacizumab [ Time Frame: Pre-dose (0 hours) on Day 1 of Cycles 1 and 2 and at 120 days after treatment discontinuation (up to 5 years) ]

Eligibility


Minimum Age:	18 Years
Maximum Age:
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	No
Criteria:	Inclusion Criteria: Adults greater than or equal to (>/=) 18 years of age Definitive diagnosis of unresectable locally advanced or metastatic RCC with clear cell histology and/or a component of sarcomatoid carcinoma, with no prior treatment in the metastatic setting Evaluable Memorial Sloan Kettering Cancer Center (MSKCC) risk score Measurable disease as defined by RECIST v1.1 Karnofsky performance status (KPS) >/=70% Adequate hematologic and end-organ function Exclusion Criteria: Radiotherapy for RCC within 14 days prior to treatment Central nervous system (CNS) disease Uncontrolled pleural effusion, pericardial effusion, or ascites Uncontrolled hypercalcemia Any other malignancies within 5 years except for low-risk prostate cancer or those with negligible risk of metastasis or death Life expectancy less than (<) 12 weeks Participation in another experimental drug study within 4 weeks prior to treatment Pregnant or lactating women Known hypersensitivity to any component of atezolizumab or other study medication History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis Positive human immunodeficiency virus (HIV) test Active or chronic hepatitis B or C Severe infection within 4 weeks prior to treatment Exposure to oral or intravenous (IV) antibiotics within 2 weeks prior to treatment Live attenuated vaccines within 4 weeks prior to treatment, 28 days prior to randomization, during treatment, or 90 days from last dose of atezolizumab Significant cardiovascular disease Prior allogeneic stem cell or solid organ transplantation Prior treatment with cluster of differentiation (CD)-137 agonists, anti-cytotoxic T-lymphoctye associated protein (CTLA)-4, anti-programmed death (PD)-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or immunosuppressive agents within 2 weeks prior to treatment History of hypertensive crisis or hypertensive encephalopathy Baseline electrocardiogram (ECG) showing corrected QT interval greater than (>) 460 milliseconds (ms)

Contacts/Locations


Central Contact Person:	Reference Study ID Number: WO29637 www.roche.com/about_roche/roche_worldwide.htm Telephone: 888-662-6728 (U.S. and Canada) Email: global.rochegenentechtrials@roche.com
Study Officials:	Clinical Trials Study Director Hoffmann-La Roche
Locations:	United States, Arizona
	[Active, not recruiting] Tucson, Arizona, United States, 85724
	United States, California
	[Active, not recruiting] Orange, California, United States, 92868
	[Active, not recruiting] San Francisco, California, United States, 94143
	United States, Colorado
	[Active, not recruiting] Aurora, Colorado, United States, 80045
	[Active, not recruiting] Denver, Colorado, United States, 80218
	United States, District of Columbia
	[Completed] Washington, District of Columbia, United States, 20016-1468
	United States, Florida
	[Active, not recruiting] Boca Raton, Florida, United States, 33486
	[Active, not recruiting] Port Charlotte, Florida, United States, 33980
	[Active, not recruiting] St Petersburg, Florida, United States, 33705
	[Terminated] West Palm Beach, Florida, United States, 33401
	United States, Georgia
	[Active, not recruiting] Atlanta, Georgia, United States, 30318
	[Terminated] Macon, Georgia, United States, 31201
	[Terminated] Marietta, Georgia, United States, 30060
	United States, Illinois
	[Active, not recruiting] Chicago, Illinois, United States, 60637
	United States, Kentucky
	[Active, not recruiting] Louisville, Kentucky, United States, 40402
	United States, Massachusetts
	[Active, not recruiting] Boston, Massachusetts, United States, 02114
	[Active, not recruiting] Boston, Massachusetts, United States, 02115
	[Active, not recruiting] Boston, Massachusetts, United States, 02215
	United States, Nevada
	[Active, not recruiting] Las Vegas, Nevada, United States, 89169
	United States, New Jersey
	[Active, not recruiting] Hackensack, New Jersey, United States, 07601
	United States, New York
	[Active, not recruiting] Albany, New York, United States, 12208
	[Active, not recruiting] New York, New York, United States, 10065
	United States, Ohio
	[Active, not recruiting] Cincinnati, Ohio, United States, 45242
	[Active, not recruiting] Cleveland, Ohio, United States, 44195
	United States, Oregon
	[Active, not recruiting] Tualatin, Oregon, United States, 97062
	United States, Pennsylvania
	[Terminated] Pittsburgh, Pennsylvania, United States, 15212
	United States, Tennessee
	[Active, not recruiting] Chattanooga, Tennessee, United States, 37404
	[Active, not recruiting] Nashville, Tennessee, United States, 37203
	[Active, not recruiting] Nashville, Tennessee, United States, 37232
	United States, Texas
	[Active, not recruiting] Dallas, Texas, United States, 75246
	[Active, not recruiting] Fort Worth, Texas, United States, 76104
	United States, Virginia
	[Active, not recruiting] Raonoke, Virginia, United States, 24014
	United States, Washington
	[Active, not recruiting] Seattle, Washington, United States, 98109
	Australia, New South Wales
	[Recruiting] Camperdown, New South Wales, Australia, 2050
	[Active, not recruiting] Macquarie University, New South Wales, Australia, 2109
	[Active, not recruiting] Waratah, New South Wales, Australia, 2298
	Australia, Queensland
	[Recruiting] South Brisbane, Queensland, Australia, 4101
	Australia, South Australia
	[Active, not recruiting] Kurralta Park, South Australia, Australia, 5037
	Australia, Victoria
	[Active, not recruiting] Heidelberg, Victoria, Australia, 3084
	Australia, Western Australia
	[Recruiting] Murdoch, Western Australia, Australia, WA6150
	Bosnia and Herzegovina
	[Recruiting] Banja Luka, Bosnia and Herzegovina, 78000
	Brazil, RS
	[Recruiting] Ijui, RS, Brazil, 98700-000
	[Not yet recruiting] Porto Alegre, RS, Brazil, 90020-090
	[Recruiting] Porto Alegre, RS, Brazil, 90610-000
	Brazil, SP
	[Recruiting] Sao Paulo, SP, Brazil, 01246-000
	Canada
	[Active, not recruiting] Quebec, Canada, G1R 3S1
	Canada, Nova Scotia
	[Recruiting] Halifax, Nova Scotia, Canada, B3H 2Y9
	Canada, Ontario
	[Active, not recruiting] Barrie, Ontario, Canada, L4M 6M2
	[Active, not recruiting] Hamilton, Ontario, Canada, L8V 5C2
	[Recruiting] London, Ontario, Canada, N6A 4L6
	[Active, not recruiting] Oshawa, Ontario, Canada, L1G 2B9
	[Active, not recruiting] Ottawa, Ontario, Canada, K1H 8L6
	[Recruiting] Toronto, Ontario, Canada, M4N 3M5
	[Recruiting] Toronto, Ontario, Canada, M5G 2M9
	Canada, Quebec
	[Active, not recruiting] Montreal, Quebec, Canada, H3T 1E2
	Czech Republic
	[Active, not recruiting] Brno, Czech Republic, 656 53
	[Recruiting] Olomouc, Czech Republic, 775 20
	[Recruiting] Praha 2, Czech Republic, 128 08
	[Recruiting] Praha 4 - Krc, Czech Republic, 140 59
	Denmark
	[Active, not recruiting] Aarhus C, Denmark, 8000
	[Recruiting] Herlev, Denmark, 2730
	[Active, not recruiting] Odense, Denmark, 5000
	France
	[Recruiting] Angers, France, 49055
	[Recruiting] Bordeaux, France, 33075
	[Recruiting] Caen, France, 14076
	[Recruiting] Lille, France, 59020
	[Recruiting] Lyon, France, 69373
	[Recruiting] Marseille, France, 13273
	[Recruiting] Nancy, France, 54100
	[Recruiting] Paris, France, 75475
	[Active, not recruiting] Paris, France, 75908
	[Recruiting] Saint Herblain, France, 44805
	[Recruiting] Villejuif, France, 94805
	Germany
	[Recruiting] Dresden, Germany, 01307
	[Recruiting] Essen, Germany, 45122
	[Recruiting] Heidelberg, Germany, 69120
	[Recruiting] München, Germany, 81377
	[Recruiting] Tübingen, Germany, 72076
	Italy, Campania
	[Recruiting] Napoli, Campania, Italy, 80131
	Italy, Emilia-Romagna
	[Recruiting] Meldola, Emilia-Romagna, Italy, 47014
	[Recruiting] Modena, Emilia-Romagna, Italy, 41100
	Italy, Lazio
	[Recruiting] Roma, Lazio, Italy, 00152
	Italy, Lombardia
	[Recruiting] Milano, Lombardia, Italy, 20132
	[Recruiting] Milano, Lombardia, Italy, 20162
	[Recruiting] Pavia, Lombardia, Italy, 27100
	Italy, Toscana
	[Recruiting] Arezzo, Toscana, Italy, 52100
	Japan
	[Active, not recruiting] Aichi, Japan, 466-8560
	[Active, not recruiting] Chiba, Japan, 260-0801
	[Active, not recruiting] Fukuoka, Japan, 812-8582
	[Recruiting] Gunma, Japan, 371-8511
	[Active, not recruiting] Ibaraki, Japan, 305-8576
	[Active, not recruiting] Iwate, Japan, 020-8505
	[Active, not recruiting] Kanagawa, Japan, 236-0004
	[Active, not recruiting] Kanagawa, Japan, 252-0375
	[Active, not recruiting] Kumamoto, Japan, 860-8556
	[Recruiting] Niigata, Japan, 951-8520
	[Recruiting] Okayama, Japan, 700-8558
	[Active, not recruiting] Osaka, Japan, 537-8511
	[Recruiting] Osaka, Japan, 545-8586
	[Active, not recruiting] Osaka, Japan, 565-0871
	[Active, not recruiting] Osaka, Japan, 589-8511
	[Active, not recruiting] Saitama, Japan, 350-1298
	[Recruiting] Sapporo-shi, Japan, 060-8648
	[Active, not recruiting] Tokushima, Japan, 770-8503
	[Active, not recruiting] Tokyo, Japan, 105-8470
	[Recruiting] Tokyo, Japan, 113-8519
	[Recruiting] Tokyo, Japan, 113-8603
	[Active, not recruiting] Tokyo, Japan, 135-8550
	[Recruiting] Tokyo, Japan, 160-0016
	[Active, not recruiting] Tokyo, Japan, 162-0054
	Korea, Republic of
	[Recruiting] Daejeon, Korea, Republic of, 35015
	[Recruiting] Gyeonggi-do, Korea, Republic of, 10408
	[Active, not recruiting] Gyeonggi-do, Korea, Republic of, 13620
	[Recruiting] Seoul, Korea, Republic of, 03080
	[Recruiting] Seoul, Korea, Republic of, 03722
	[Recruiting] Seoul, Korea, Republic of, 05505
	[Active, not recruiting] Seoul, Korea, Republic of, 06351
	Mexico
	[Recruiting] Queretaro, Mexico, 76090
	[Recruiting] Toluca, Mexico, 50180
	[Not yet recruiting] Veracruz, Mexico, 91700
	Poland
	[Recruiting] Bydgoszcz, Poland, 85-796
	[Recruiting] Lodz, Poland, 93-513
	[Recruiting] Lublin, Poland, 20-090
	[Recruiting] Poznan, Poland, 60-569
	[Recruiting] Warsaw, Poland, 02-616
	[Recruiting] Warszawa, Poland, 04-125
	Russian Federation
	[Recruiting] Barnaul, Russian Federation, 656049
	[Recruiting] Moscow, Russian Federation, 125284
	[Recruiting] Moscow, Russian Federation, 143423
	[Recruiting] Nizhni Novgorod, Russian Federation, 603001
	Singapore
	[Recruiting] Singapore, Singapore, 119074
	[Recruiting] Singapore, Singapore, 169610
	[Recruiting] Singapore, Singapore, 258499
	Spain
	[Recruiting] Barcelona, Spain, 08035
	[Recruiting] Barcelona, Spain, 08036
	[Recruiting] Barcelona, Spain, 08041
	[Active, not recruiting] Barcelona, Spain, 08907
	[Active, not recruiting] Cordoba, Spain, 14004
	[Active, not recruiting] Madrid, Spain, 28007
	[Recruiting] Madrid, Spain, 28034
	[Recruiting] Madrid, Spain, 28041
	[Recruiting] Sevilla, Spain, 41013
	Spain, Barcelona
	[Active, not recruiting] Sabadell, Barcelona, Spain, 08208
	Spain, Guipuzcoa
	[Not yet recruiting] San Sebastian, Guipuzcoa, Spain, 20080
	Taiwan
	[Recruiting] Taichung, Taiwan, 407
	[Recruiting] Taipei, Taiwan, 100
	[Active, not recruiting] Taoyuan, Taiwan, 333
	Thailand
	[Recruiting] Bangkok, Thailand, 10330
	[Recruiting] Bangkok, Thailand, 10400
	[Recruiting] Bangkok, Thailand, 10700
	[Recruiting] Chiangmai, Thailand, 50200
	[Recruiting] Songkhla, Thailand, 90110
	Turkey
	[Recruiting] Ankara, Turkey, 6100
	[Recruiting] Edirne, Turkey, 22770
	[Active, not recruiting] Istanbul, Turkey, 34300
	United Kingdom
	[Active, not recruiting] Bebington, United Kingdom, CH63 4JY
	[Active, not recruiting] Birmingham, United Kingdom, B15 2TH
	[Active, not recruiting] Blackburn, United Kingdom, BB2 3HH
	[Recruiting] Cambridge, United Kingdom, CB2 0QQ
	[Recruiting] London, United Kingdom, EC1A 7BE
	[Recruiting] London, United Kingdom, NW3 2QG
	[Active, not recruiting] London, United Kingdom, SW3 6JJ
	[Recruiting] Manchester, United Kingdom, M2O 4BX
	[Recruiting] Oxford, United Kingdom, OX3 7LJ
	[Active, not recruiting] Southampton, United Kingdom, SO16 6YD
	[Recruiting] Sutton, United Kingdom, SM2 5PT
	[Recruiting] Swansea, United Kingdom, SA2 8QA

IPDSharing


Plan to Share IPD:

References


Links:
Available IPD/Information: